Sickle Cell Disease: Voxelotor, Crizanlizumab, and Gene Therapy
Disease-Modifying Therapies: Beyond Hydroxyurea
Hydroxyurea has been the cornerstone of sickle cell disease (SCD) management since 1998, increasing fetal hemoglobin (HbF) by 10-20% and reducing vaso-occlusive crises (VOCs) by 44% (MSH trial). However, approximately 30-40% of patients have inadequate response or intolerance. Three novel agents target distinct pathophysiologic mechanisms: voxelotor (HbS polymerization inhibitor), crizanlizumab (P-selectin blocker preventing vaso-occlusion), and L-glutamine (antioxidant reducing red cell adhesion). These agents are used as add-on therapies to hydroxyurea when disease control remains suboptimal.
Voxelotor: Targeting Hemoglobin Polymerization
Voxelotor 1,500 mg daily stabilizes hemoglobin in the oxygenated (R-state) conformation, inhibiting HbS polymerization and sickling. The HOPE trial demonstrated a hemoglobin increase of greater than 1 g/dL in 51% of patients versus 7% with placebo (p < 0.001) at 24 weeks, with corresponding reductions in indirect bilirubin and reticulocyte counts indicating decreased hemolysis. However, the impact on VOC frequency in HOPE was not statistically significant, and subsequent real-world data have raised questions about clinical event reduction despite hematologic improvement. Voxelotor is most appropriately positioned for patients with significant anemia (hemoglobin below 8 g/dL) causing symptomatic limitation despite hydroxyurea optimization.
Crizanlizumab: Anti-Adhesion Therapy
Crizanlizumab, a P-selectin monoclonal antibody administered 5 mg/kg IV monthly, reduced annual VOC rate by 45% (1.63 vs 2.98 events per year, p = 0.010) in the SUSTAIN trial. However, the larger confirmatory STAND trial (enrolling 400+ patients on stable hydroxyurea) failed to show a significant reduction in VOCs for the primary endpoint, creating uncertainty about the magnitude of clinical benefit. Crizanlizumab may be most beneficial for patients with frequent VOCs (3 or more per year) despite maximized hydroxyurea who are not candidates for gene therapy. Infusion reactions occur in approximately 3% of patients.
Sponsored
Gene Therapy: Lovotibeglogene and Exagamglogene Autotemcel
Lovotibeglogene autotemcel (lovo-cel, Lyfgenia) uses lentiviral vector gene addition to produce anti-sickling hemoglobin (HbAT87Q). In the Phase 3 trial, 88% of evaluable patients achieved VOC-free status for at least 12 consecutive months post-infusion, with total hemoglobin of 11-14 g/dL. Exagamglogene autotemcel (exa-cel, Casgevy) uses CRISPR-Cas9 gene editing to reactivate fetal hemoglobin production by disrupting BCL11A. In pivotal data, 97% of evaluable patients were VOC-free for at least 12 consecutive months, with HbF levels of 40-50%. Both require myeloablative conditioning with busulfan, carrying risks of infertility, secondary malignancy, and prolonged cytopenias.
Patient Selection for Gene Therapy
Gene therapy candidates are patients aged 12 and older with severe SCD characterized by recurrent VOCs (4 or more per year), acute chest syndrome, or significant end-organ damage despite optimized conventional therapy. Cost (exceeding $2 million), limited manufacturing capacity, and the requirement for specialized transplant centers remain major access barriers. Patients must weigh the potential for functional cure against conditioning-related risks, including a small but non-zero risk of myelodysplasia and leukemia observed with lentiviral-based approaches. Allogeneic hematopoietic stem cell transplant from matched sibling donors remains an established curative option with greater than 90% overall survival and 85-90% event-free survival.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.